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Background: Patients with acute myocardial infarction (AMI) are more likely to develop long-term cardiovascular events. antiplatelet therapy 
(DAPT) is considered optimal in patients implanted with drug-eluting stents (DES), the risk-benefit rato for longer-term DAPT in AMI patients treated 
with DES remains poorly defined.
methods: We analyzed consecutively 2293 AMI patients on DAPT who had not had any adverse events such as death, nonfatal MI, stroke or any 
revascularization and TIMI major bleeding throughout 1 year in the COREA-AMI (COnvergent REgistry of cAtholic and chonnAm university for AMI) 
enrolled from January 2004 to December 2009. Patients were grouped according to the duration of DAPT (group 1, 12-18 months; group 2, 18-24 
months; group 3, longer than 24 months). The primary outcome was a composite of all-cause death, nonfatal MI or stroke.
results: The clinical and angiographic characteristics were similar among three groups. Median follow up duration was 941 days (interquartile 
range 601 - 1412). As DAPT duration increased, the primary outcome was significantly reduced (18.0% vs. 10.2% vs. 8.9%, P for trend < 0.001). In 
addition, we observed the longer the DAPT duration, the less the cumulative rate of death or a composite of death or MI (P for all-cause death and P 
for a composite of all-cause death or MI <0.001 in all). There was no difference in the cumulative rates of bleeding among three groups. Notably, as 
the duration of DAPT gets longer, the relative risk for primary outcome was reduced 3.7 % per 1 month (hazard ratio 0.96, 95% confidence interval 
0.95-0.97) in Cox proportional hazard regression model.
conclusions: In patients with AMI undergoing DES implantation, longer duration of DAPT more than 12 months significantly improved clinical 
outcome in this real-world registry.
